Jingwei Lu

Chief Executive Officer at Synlico.

South San Francisco, CA
Form D signer
Synlico

Raised on Synlico filings

$3M

of $3M offered across 1 Form D filing

Form D filings: 1
Last filing: Feb 25, 2025

Company

Biotech · South San Francisco, CA

Engineered T cell therapies for solid tumors

Engineered T cell therapies for solid tumors

Investors: 1
Founded: 2021

Investors: 1
Sector: Biotech
Founded: 2021
HQ: South San Francisco, CA

Synlico filings

Synlico Form D filings
Filed	Security	Sold of offered	Filing
Feb 25, 2025	Equity	$3M/ $3M	Form D

EquityFiled Feb 25, 2025Form D
$3M/ $3M